Cardiac glycosides in cancer research and cancer therapy

Area of Science:

• Pharmacology
• Oncology
• Biochemistry

Background:

• Cardiac glycosides are known to inhibit Na+, K+-ATPase, increasing intracellular Ca2+ and influencing cell signaling pathways.
• This mechanism suggests potential roles in apoptosis and cell proliferation, particularly in cancer.
• Cardiac glycosides have demonstrated anti-proliferative and apoptosis-inducing effects in prostate cancer cells at clinically relevant concentrations.

Purpose of the Study:

• To investigate the potential of cardiac glycosides as antineoplastic agents.
• To explore the correlation between cardiac glycoside efficacy and topoisomerase II inhibition.
• To examine the effects of cardiac glycosides on angiogenesis and transcription factors relevant to cancer.

Main Methods:

• Analysis of Na+, K+-ATPase inhibition and intracellular Ca2+ levels.
• Assessment of cancer cell proliferation and apoptosis induction.
• Evaluation of DNA-topoisomerase II cleavable complex formation.
• Investigation of fibroblast growth factor-2 (FGF-2) and NF-kappaB regulation.

Main Results:

• Cardiac glycosides, including digitoxin, inhibit cancer cell growth and induce apoptosis.
• The degree of cancer cell growth inhibition correlates with topoisomerase II-inhibiting activity.
• Digitoxin at therapeutic concentrations induces DNA-topoisomerase II cleavable complexes, similar to etoposide.
• Cardiac glycosides can regulate FGF-2 and inhibit NF-kappaB activation, key targets in anticancer drug development.

Conclusions:

• Cardiac glycosides exhibit significant antineoplastic potential through multiple mechanisms.
• Their ability to inhibit topoisomerase II and regulate angiogenesis factors makes them promising candidates for cancer therapy.
• Oleander extracts, such as Anvirzel, are being developed as novel cancer treatments based on these findings.